Navigation Links
New vaccine delivery may be more effective against measles

Worldwide, there are estimated to be 10 million cases of measles and 197,000 deaths from the disease each year. While vaccines exist to protect children against measles, the vaccines are often difficult to store, costly to transport and may be prone to contamination when shipped to developing countries. Research to be presented at the 2009 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition will reveal new methods for delivering measles vaccines that could potentially reduce costs and improve safety.

"Vaccination has become controversial in some international communities which believe vaccines might be hazardous," said Robert Sievers, Ph.D., from the University of Colorado and one of the study's principal investigators. "However, in many parts of the world, the disease itself is a serious hazard, killing hundreds of thousands of children each year."

While a liquid vaccine using a hypodermic needle is presently the only way to prevent the disease, Dr. Sievers' study shows promise for a new method that allows the patient to inhale a finely-powdered. In order to produce the inhalant, the weakened measles virus must be mixed with high-pressure carbon dioxide to produce microscopic bubbles and droplets, which are then gently dried to produce an inhalable powder. The powder is then puffed into a small inhaler-like device and administered. The aerosol vaccine was shown effective in test animals, and human trials are expected to begin next year in India, where more than half of the world's measles cases occur.

Researchers from Aridis Pharmaceuticals also have been working to develop a room temperature stable measles formulation that can be easily inhaled using cost-effective dry-powder inhalers in collaboration with the non-profit foundation PATH. According to Satoshi Ohtake, Ph.D., from Aridis and the study's principal investigator, "There is a need for technologies that could stabilize the measles vaccine, as this would facilitate mass vaccination in developing world countries where transport, storage, administration costs and other complexities have limited vaccine coverage by 70 percent."

Dr. Ohtake's study used a combination of mild spray drying process conditions and unique stabilizers to produce stable dry powders with excellent preservation of vaccine activity. The potency of the dried vaccine was then tested while being stored at different temperatures over several week-long periods. The results found that the dry-powdered aerosol was stable for at least eight weeks at 37C, surpassing the World Health Organization requirement for heat stability of one week at similar storage conditions.

"This study offers hope for developing countries that desperately need more stable and efficient vaccination methods," says Dr. Ohtake. "This new method could potentially offer safer, more affordable and effective treatments to patients that need them the most."


Contact: Rosalind D'Eugenio
American Association of Pharmaceutical Scientists

Related medicine news :

1. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
2. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
3. Vaccine Stops Alzheimers Brain Tangles
4. Human Papilloma Virus vaccines may decrease chances of oral cancer
5. U.S. Teens Fall Short on Vaccine Coverage
6. Nasal Anthrax Vaccine Proves Effective in Animal Study
7. Hot ice, measuring depression, perfect invisibility and flu vaccine incentives
8. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
9. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
10. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
11. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
Post Your Comments:
(Date:11/24/2015)... , ... November 24, 2015 , ... In an ... restrictions and variables that determine which patients are or are not eligible for bariatric ... have a BMI over 40, are more than 100 pounds overweight, or have a ...
(Date:11/24/2015)... UT (PRWEB) , ... November 24, 2015 , ... It ... Magazine. For a business, it is critical that the first impression be positive and ... they are not likely to buy anything or want to return. They will also ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... gather to share their knowledge and experiences at a live taping of the ... Ruesch Center for the Cure of Gastrointestinal Cancers 2015 Symposium at Georgetown University ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Aided by ... today announced an innovative study designed to yield insights into how to detect and ... of biomarkers for pancreatic cancer from small, non-coding RNA molecules (ncRNA), genetic material that ...
(Date:11/24/2015)... ... November 24, 2015 , ... Sir Grout of Baltimore is ... certification. The award recognizes good companies for excellence in service and a commitment ... and hard surface restoration company earned this recognition after a thorough review by ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... November 24, 2015 F1000Workspace - ... - since it was launched just six months ago. ... and authoring platform for scientists - since it was launched ... have been loaded on to F1000Workspace - a ... since it was launched just six months ago. ...
(Date:11/24/2015)... YORK , Nov. 24, 2015 iRhythm Technologies, ... advancing cardiac care, today announced that it will participate in the ... Hotel in New York, NY . ... present on Tuesday December 1, 2015 at 8:50am ET. ... . --> . ...
(Date:11/24/2015)... uptake of recently approved and pipeline premium products for Type 1 Diabetes ... says GBI Research . --> The ... Mellitus (T1DM), will be a key driver of market growth to 2021, ... The uptake of recently approved and pipeline premium products for Type 1 ... 2021, says GBI Research . Type ...
Breaking Medicine Technology: